相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Toxicology Strategies for Drug Discovery: Present and Future
Eric A. G. Blomme et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2016)
The influence of subclonal resistance mutations on targeted cancer therapy
Michael W. Schmitt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
A. Stewart et al.
ANNALS OF ONCOLOGY (2015)
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L. Apetoh et al.
ANNALS OF ONCOLOGY (2015)
HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
Pooja P. Advani et al.
BIOMARKERS IN MEDICINE (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
John W. Cassidy et al.
CANCER RESEARCH (2015)
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Celina Garcia-Garcia et al.
CLINICAL CANCER RESEARCH (2015)
Translational Implications of Tumor Heterogeneity
Mariam Jamal-Hanjani et al.
CLINICAL CANCER RESEARCH (2015)
Drugging PI3K in cancer: refining targets and therapeutic strategies
Timothy A. Yap et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
Han Kiat Ho et al.
DRUG METABOLISM REVIEWS (2015)
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
Rachel N. Grisham et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer.
Rona D. Yaeger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap
David R. Gandara et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Expanded RAS: Refining the Patient Population
Chloe E. Atreya et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
Stephen R. D. Johnston
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob et al.
LANCET ONCOLOGY (2015)
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Junwei Shi et al.
NATURE BIOTECHNOLOGY (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
Pathway and network analysis of cancer genomes
Pau Creixell et al.
NATURE METHODS (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune checkpoint modulation: Rational design of combination strategies
Dmitriy Zamarin et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
Erin M. Tricker et al.
CANCER DISCOVERY (2015)
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Antoni Ribas
CANCER DISCOVERY (2015)
Systems biology approaches for advancing the discovery of effective drug combinations
Karen A. Ryall et al.
JOURNAL OF CHEMINFORMATICS (2015)
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
Timothy J. Stuhlmiller et al.
CELL REPORTS (2015)
Distinctive Behaviors of Druggable Proteins in Cellular Networks
Costas Mitsopoulos et al.
PLOS COMPUTATIONAL BIOLOGY (2015)
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells
Anil Korkut et al.
ELIFE (2015)
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
Stephen R. D. Johnston
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2015)
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bedard et al.
CLINICAL CANCER RESEARCH (2015)
Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
Rituparna Das et al.
JOURNAL OF IMMUNOLOGY (2015)
Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays
Jonathan A. Lee et al.
PLOS ONE (2015)
PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma
Marian M. Deuker et al.
CANCER DISCOVERY (2015)
A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way?
Jessica Taylor et al.
JOURNAL OF BIOMOLECULAR SCREENING (2015)
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
Christina Therkildsen et al.
ACTA ONCOLOGICA (2014)
A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
L. Rhoda Molife et al.
CLINICAL CANCER RESEARCH (2014)
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Neil A. O'Brien et al.
CLINICAL CANCER RESEARCH (2014)
Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Oriana Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: Beyond KRAS Testing
Noman Ashraf et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
Tomoko Smyth et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
Antoni Ribas et al.
LANCET ONCOLOGY (2014)
The clinical development of MEK inhibitors
Yujie Zhao et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
RNAi screening comes of age: improved techniques and complementary approaches
Stephanie E. Mohr et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Applying Synthetic Lethality for the Selective Targeting of Cancer
Donal P. McLornan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer
Geraldine Perkins et al.
PHARMACOGENOMICS (2014)
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models
Luke Whitesell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Hikmat Al-Ahmadie et al.
CANCER DISCOVERY (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
Shirish M. Gadgeel et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Carolyn D. Britten
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
Emanuela Romano et al.
CLINICAL CANCER RESEARCH (2013)
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon et al.
CLINICAL CANCER RESEARCH (2013)
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
Maja J. A. de Jonge et al.
INVESTIGATIONAL NEW DRUGS (2013)
Genetics and biomarkers in personalisation of lung cancer treatment
Rafael Rosell et al.
LANCET (2013)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Safety and feasibility of targeted agent combinations in solid tumours
Sook Ryun Park et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
Michael Pourdehnada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Systems Pharmacology of Adverse Event Mitigation by Drug Combinations
Shan Zhao et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke et al.
NATURE COMMUNICATIONS (2013)
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Matthew A. Held et al.
CANCER DISCOVERY (2013)
A Systems Biology Approach to Personalizing Therapeutic Combinations
Lawrence N. Kwong et al.
CANCER DISCOVERY (2013)
Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
Maria Teresa Herrera-Abreu et al.
CANCER DISCOVERY (2013)
Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Madhu S. Kumar et al.
CELL (2012)
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
Michael Steckel et al.
CELL RESEARCH (2012)
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Toshio Shimizu et al.
CLINICAL CANCER RESEARCH (2012)
It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
Jason R. Westin et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani et al.
NATURE BIOTECHNOLOGY (2012)
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Lawrence N. Kwong et al.
NATURE MEDICINE (2012)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Evolution of the cancer genome
Lucy R. Yates et al.
NATURE REVIEWS GENETICS (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Robert J. Gillies et al.
NATURE REVIEWS CANCER (2012)
Combining immunotherapy and targeted therapies in cancer treatment
Matthew Vanneman et al.
NATURE REVIEWS CANCER (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Targeting IGF-1R: throwing out the baby with the bathwater?
B. Basu et al.
BRITISH JOURNAL OF CANCER (2011)
Mutant BRAF Melanomas-Dependence and Resistance
Poulikos I. Poulikakos et al.
CANCER CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis
Sergio Iadevaia et al.
CANCER RESEARCH (2010)
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Lee M. Ellis et al.
CLINICAL CANCER RESEARCH (2009)
From Theoretical Synergy to Clinical Supra-Additive Toxicity
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Harnessing genetically engineered mouse models for preclinical testing
Ana I. Robles et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2008)
Models from experiments: combinatorial drug perturbations of cancer cells
Sven Nelander et al.
MOLECULAR SYSTEMS BIOLOGY (2008)
The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action
Margaret S. Lee et al.
CANCER RESEARCH (2007)
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst et al.
NATURE (2007)
Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer
M O'Grady et al.
BMC CANCER (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Multicomponent therapeutics for networked systems
CT Keith et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
